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S260 Poster Session IThere were 22 males, 18 females, ages 7 mo – 18.7 yrs, median 5.5
years. Stem cell sources for the msibs were marrow for 7 and PBSC
for 11. Conditioning regimen was fTBI based in 25, busulfan based
in 15–of those, 5 were reduced intensity. Graft-versus-host disease
prophylaxis included cyclosporin A and either methotrexate (n 5
35) or mycophenolate (n 5 5). Disease status at time of HSCT
was CR1 in 23, 11 were in CR2 and 6 had evidence of residual
AML (5% by morphology or [+] cytogenetics).
The median time to reach an ANC. 500/ml was 18 days (29 days
for UCB vs 12 after m/PBSC). An unsupported Plt Ct . 20,000/ml
was achieved in 36 pts at a median of 21 days (49 for UCB vs 13 after
m/PBSC). 4 UCB pts failed to engraft with donor hematopoiesis. 14
pts developed Gr II-IV acute GVHD, 8 of the 35 pts surviving more
than 100 days developed chronic GVHD (2 limited, 6 extensive). 9
UCB and 5 m/PBSC pts developed acute GVHD. 7 m/PBSC pa-
tients but only 1 UCB patient developed chronic GVHD.
Overall survival (OS) rates 3 years post HSCT were similar when
comparing UCB recipients (63%) versus combined matched m/
PBSC donors (78%), respectively. This result is despite the higher
proportion of CR2 and PR patients in the UCB cohort (64 vs
17%). OS of patients in CR1 and CR2 at the time of HSCT are
87 % and 43 % respectively.
Table 1. HSCT for Pediatric AML-msib v UCB
All pts, Matched UCB,
n540 sibs, n518 n522Male–Female 22–18 12–6 10–12
Age (yrs, median +/2 sd) 5.5 +/2 5.6 11.6 +/2 5.7 3.5 +/2 4.2
Weight (kg, median) 21 38 15
Diagnosis to HSCT (mo, median) 5.1 3.5 6.4
CR1 23 15 8
CR2 or PR 17 3 14fTBI-VP-CY 25 8 17
Bu4-CY+/2VP 10 6 4
Flu-Bu2 +/2 ATG 5 4 1ANC engraft (days, median) 18 12 29
Platelet engraft (days, median) 21 13 49
Non-engraft 4 4
TRM 5 1 4
Relapse 8 4 4
Overall Survival (%) 69 78 63Our experience supports continued consideration of allogeneic
HSCT for pediatric AML in CR1 utilizing matched sibling donors.
The results using unrelated UCB stem cell sources suggest that
young AML patients lacking a msib donor should search for an
UCB match and consider that option for HSCT in CR1. Methods
to enhance engraftment/limit rejection of UCB could potentially
further improve the results using UCB stem cells.291
HIGH DOSE CARBOPLATIN, ETOPOSIDE, MELPHALAN AND AUTOLO-
GOUS HEMATOPOIETIC STEM CELL RESCUE WITH FOR THE TREATMENT
OF RELAPSED PEDIATRIC GERM CELL TUMORS
Villela, N.C., Gouveia, R.V., Macedo, C.R.D.P., Zecchin, V.G.,
Ginani, V.C., Marconcini, J.F., Felix, O.M.O., Barros, D.P.,
Alves, L.R., Ibanez, A., Simoes, P.C., Silva, A.G., Petrilli, A.S.,
Seber, A. Instituto de Oncologia Pediatrica, S~ao Paulo, SP, Brazil
High dose chemotherapy with autologous hematopoietic stem cell
transplantation (HSCT) is the treatment of choice for relapsed or re-
fractory germ cell tumors (GCT) but few pediatric patients are in-
cluded in most reports. Our objective is to describe the
institutional experience with autologous HSCT for GCT.
Results: From November, 2001 to October, 2010, 11 patients with
GCT underwent HSCT after conditioning therapy with carboplatin
(425 mg/m2/day x 4 days), etoposide (337.5 mg/m2/day x 4 days) and
melphalan (70 mg/m2/day x 2 days) - doses for children older than 2
years of age and with normal renal function. Their median age was
12.5 years (2-19)and seven were female. One had primary centralnervous system (CNS) tumor, 6 gonadal and 4 extra-gonadal tumors.
Most patients had been treated according to the Brazilian GCTPro-
tocol-99 and received TIP – paclitaxel, ifosfamide and cisplatin as
second line chemotherapy. One patient was in the first remission
of a testicular tumor with trophoblastic component and multiple
brain and lung metastases; seven were in second remission; one
was in third remission and two had refractory disease with partial re-
sponse to therapy. All patients had a normal bone marrow aspirate
and biopsy prior to stem cell collection. Eight patients had periph-
eral blood stem cell harvest, one marrow, and one both, for a target
cell dose of 5 million CD34 cells/kg. All patients had febrile neutro-
penia (seven also had positive blood cultures), oral mucositis (all
needed IVmorphine) and diarrhea. One 3-year-old girl in second re-
mission had a CNS bleeding and died two months after HSCT. Five
patients had disease progression or relapse, three of them with ad-
vanced diseases. Five patients are alive in complete remission with
a median follow up of 6.8 years (2-8 years). In conclusion, GCT is
a rare indication of autologous HSCT in pediatrics (11/123 autolo-
gous transplants in 10 years). Despite acceptable results in adults
with refractory diseases, the best timing for autologous transplanta-
tion in pediatrics seems to be second remission. Carboplatin, etopo-
side and melphalan, the same regimen that has been used for many
years for stage 4 neuroblastoma, is associated with considerable tox-
icity but four of six evaluable patients with GCT in second remission
remain tumor-free more than six years after transplant.292
FLUDARABINE, BUSULFAN, AND ALEMTUZUMAB AS A REDUCEDTOXICITY
REGIMEN FOR CHILDREN WITH MARROW STEM CELL DEFECTS AND
MALIGNANCY IMPROVES ENGRAFTMENT AND GRAFT VERSUS HOST
DISEASE WITHOUT DELAYING IMMUNE RECONSTITUTION
Law, J.1, Cowan, M.J.1, Dvorak, C.C.1, Baxter-Lowe, L.A.3,
Musick, L.2, Hwang, J.4, Horn, B.1 1University of California San
Francisco, San Francisco, CA; 2University of California San Francisco,
San Francisco, CA; 3University of California San Francisco, San Fran-
cisco, CA; 4University of California San Francisco, San Francisco, CA
For many children with malignancies and MSCD, allogeneic he-
matopoietic cell transplant (HCT) provides the best chance of
cure. However, toxicity of conditioning and graft failure remain
challenges. We previously reported that busulfan, fludarabine and
rabbit ATG conditioning (total dose5 8mg/kg) resulted in less tox-
icity but no improvement in engraftment rates. Alemtuzumab has
been shown to enhance engraftment and reduce rates of GVHD in
myeloablative regimens. Thus, we prospectively evaluated targeted
IV busulfan, fludarabine and Alemtuzumab (total dose 5 1.5mg/
kg) in a Phase II study of children receiving closely matched related
or unrelatedHCT. Thirty-five children were enrolled: 5 with malig-
nancies and 30 withMSCD. Twelve donors were HLAmatched rel-
atives, 16 were fully HLA allele-matched unrelated donors and 7
were 9/10 HLA allele-matched unrelated donors. No patient had
more than a Grade 2 reaction to Alemtuzumab. The most common
toxicity (n 5 15) was Grade 3 mucositis. One patient had Grade 4
mucositis. Only 1 patient developed VOD (Grade 3). 11/15 CMV
seropositive patients had reactivation and 3/17 CMV seronegative
patients had primary CMV infection.None developedCMVdisease.
Thirty-one of 34 (88%) evaluable patients achieved durable engraft-
ment. Neutrophil recovery occurred at a median of 16 days (range
10-25). Three patients (2 mismatched at 1 antigen) with MSCD
failed to engraft from unrelated donor HCT and underwent subse-
quent transplants. One is alive and progression free. For those suc-
cessfully engrafted, the median time to CD4 . 200x10e6cells/L
and PHA . 50% was 6 months with a maximum of 9 months. At
1 year post transplant, 18/19 evaluable patients had 87%ormore do-
nor chimerism in whole blood, CD14/15+ and CD19+ subsets and
71% or more donor chimerism in the CD3+ subset. One patient
had only 55% whole blood donor chimerism at 1 year but ultimately
achieved 82%. Six patients developed acute Graft versus Host Dis-
ease (GVHD) of Grade 2-4 with only 1 patient progressing to
chronic GVHD. Seven patients had disease progression/relapse
with 1 dying from disease. Four patients died of Transplant Related
Mortality (11%). At a median follow up of 29 months (range 3-74),
the EFS was 60+/2 SE9% with an Overall Survival of 81+/
Poster Session I S2612SE6%.These results suggest that replacement of rabbit ATG with
Alemtuzumab may improve engraftment and decrease GVHD rates
without resulting in delays in immune reconstitution.293
CYSTATIN C IS A MORE SENSITIVE ESTIMATE OF KIDNEY FUNCTION
THAN CREATININE IN PEDIATRIC AUTOLOGOUS BONE MARROW
TRANSPLANTATION
Laskin, B.L.1, Goebel, J.1, Bissler, J.J.1, Khoury, J.C.2, Davies, S.M.3,
Jodele, S.3 1Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH; 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Overview: Accurate assessment of kidney function is essential in the
care of bone marrow transplant (BMT) patients. Both cystatin C,
a protease inhibitor produced by all nucleated cells and measured
in a single blood sample, and creatinine are used to estimate kidney
function (glomerular filtration rate, GFR).While creatinine is influ-
enced by muscle mass, cystatin C is potentially modified by cortico-
steroids, thyroid function, and the white blood cell count (WBC).
The literature is conflicting on the validity of cystatin C measure-
ments in BMT and oncology patients, and the effect of leukopenia
is understudied. We hypothesize that cystatin C is a more sensitive
estimate of kidney function in BMT patients, while controlling for
the WBC.
Methods:We retrospectively compared cystatin C to creatinine for
predicting nuclear GFR (technetium-99m-DTPA; nucGFR) in pe-
diatric recipients of autologous BMTs. General linear mixed models
were used to calculate regression and intra-class correlation coeffi-
cients (ICC, ranging from 0-1 with higher values indicating less var-
iation/greater reliability between the estimates). Prediction models
used cystatin C GFR5 [77.24*cys21.2623] (cysGFR), with and with-
out WBC, and Schwartz GFR 5 [0.413*height (cm)/creatinine]
(schGFR).
Results: 12 patients (median age 3.5 yrs, range 2-10 yrs) underwent
29 tandem BMTs (median 2 BMTs/patient, range 1-4) for medullo-
blastoma (n5 7), neuroblastoma (n5 4), and atypical teratoid rhab-
doid tumor (n 5 1). All patients except 1 had normal thyroid
function. 3 patients received steroids (2 stress dosing and 1 high-
dose for veno-occlusive disease of the liver). GFRs (mean6std error)
in ml/min/1.73m2 (normal . 90) were 142.069.0 (nuc), 136.566.2
(cys), and 132.165.1 (sch). ICCs were 0.54 for nucGFR versus
cysGFR and 0.26 for nucGFR versus schGFR. Furthermore, the
Pearson correlation coefficient was much higher for cysGFR (0.80,
p\0.001) than for schGFR (0.22, p5 0.36) compared to nucGFR.
Regression coefficients and the 95% confidence intervals (CI) for the
prediction models are shown in the table.
Conclusions: Cystatin C was a statistically significant predictor of
nucGFR while creatinine was not. WBC was of borderline signifi-
cance in prediction of nucGFR using cysGFR. To maximize clinical
utility, future research will confirm these findings by accounting for




model for nucGFR b regression coefficients [95% CI]cysGFR* 0.96 [0.77, 1.14]
cysGFR* & WBC 1.08 [0.94, 1.23] & 0.67 [-1.02, 2.36]
schGFR 0.17 [-0.072, 0.41]*statistically significant (p<0.05)294
A MULTIDISCIPLINARY APPROACH TO ADHERENCE IMPROVEMENT US-
ING EDUCATION AND MEDICATION BOXES FOR ADOLESCENTS AND
YOUNG ADULTS WHO HAVE UNDERGONE ALLOGENEIC HEMATO-
POEITIC STEM CELL TRANSPLANTATION
McBride, J., Shinkle, M. Children’s Memorial Hospital, Chicago, IL
Achieving adherence to immunosuppressive medications in the
adolescent population of post allogeneic stem cell transplant canbe challenging. Literature has documented consistently a link be-
tween regimen complexity and adherence rates. Non-adherence
can put patients at increase risk of uncontrolled graft versus host dis-
ease. While there is literature describing adolescent barriers to ad-
herence and their attitudes regarding medications, no studies have
evaluated the use of medication boxes in combination with a multi-
disciplinary patient education on adherence. A pilot study was un-
dertaken to see if use of a medication box combined with a 15
minute discussion with a pharmacist and social worker about barriers
to adherence, the importance of medication adherence, and how to
use the box will improve adherence in adolescent post allogeneic
stem cell transplant patients. Medication boxes were initially filled
by a health care professional on the patients’ clinic day. Pill counts
were used to assess adherence rates. Patients completed surveys
about their perception on their medications prior to, during, and af-
ter the intervention. 11 patients consented to study to date (ages 13-
25); 1 patient withdrew, 1 patient died prior to start of the study, and
1 patient has yet to start. During the active medication box phase of
the study, patient’s adherence rates ranged from 57-100% with all
but one patient having an adherence rate . 80%. When study par-
ticipants where asked if they do a good job caring for themselves 7
out of 9 responded positively (somewhat to strong agreement); al-
though, 5 out of 8 reported missed doses at least once during the
study duration. Of note, 6 out of 9 participants at some point during
the study duration reported agreement or neutrality to the statement
‘I don’t think I need my medication’ and 8 out of 9 patients reported
agreement or neutrality to the statement ‘My doctors want me to
take too many medications’. These findings are of interest because
they may reflect unique characteristics of adolescent development,
how their views on their health and medications may change
throughout a treatment course, whichmay have direct effect onmed-
ication adherence. This pilot study supports the use of medication
boxes for adolescents post allogeneic stem cell transplantation. Fur-
ther studies need to be done to assess what patients would most ben-
efit by having their medication box filled for them.295
ENGRAFTMENT KINETICS IN CHILDREN AFTER REDUCED INTENSITY
CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION (RIC-
HSCT)
Schneiderman, J., Kletzel, M., Chaudhury, S., Duerst, R., Tse, W.T.
Northwestern University Feinberg School of Medicine, Children’s Memo-
rial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
The kinetics of stem cell engraftment following RIC-HSCT are
different from that of myeloablative transplant; previous analyses
are limited to adults. Between 2003 and 2010, we performed RIC-
HSCT in 88 children with malignant (n 5 40) or non-malignant
(48) diseases; none had prior HSCT. Patient characteristics are
shown in Table 1. Post-HSCT, total white cells donor chimerism
was monitored serially by variable number tandem repeat analysis
once the peripheral white blood cell count exceeded 1,000 cells/
ml. The cumulative incidence of patients reaching 50% and 90%do-
nor chimerism by +20/40/60 days post-HSCT was 67/85/86% and
41/68/72%, respectively. Eight patients (8/88 5 9%) had primary
graft failure, with chimerism never reaching 20%. Sixty-six patients
(75%) have peak chimerism over 90%, whereas 14 patients (16%)
have peak chimerism between 20-90%. Among those engrafted (n
5 82), chimerism in 57 patients (70%) was durable and did not de-
cline with time, but in 25 patients (30%), there was a drop in chime-
rism of . 10% between two consecutive measurements. Median
time of chimerism drop was +60 days post-HSCT (range 17-193
days). Seven patients (7/82 5 8%) experienced relapse of leukemia
soon after the drop was detected, 12 patients (15%) had stabilization
or improvement of chimerism after withdrawal of immunosuppres-
sion and/or donor lymphocyte infusion (DLI), and 6 patients (7%)
had no recovery despite immune manipulation, resulting in second-
ary graft failure. There is no correlation between the magnitude of
chimerism drop and the response to immune manipulation. There
were differences in engraftment kinetics among patients with malig-
nant or non-malignant diseases. In the malignant group, the cumu-
lative incidence of 90% donor chimerism at +100 days was 87.5%,
and at one year, the percentage of patients with full or mixed chime-
rism was 90% and 10%, respectively. By contrast, in the non-
